Predictive value of individualized tumor response testing by ATP-based chemotherapy response assay in ovarian cancer

Cancer Investigation

Volumn 26, Issue 4, 2008, Pages 426-430

  Han, Seung Su ^a   Choi, Sung Ho ^b   Lee, Yoo Kyung ^a   Kim, Jae Weon ^a   Park, Noh Hyun ^a   Song, Yong Sang ^a   Lee, Hyo Pyo ^a   Kang, Soon Beom ^a,c  

^a Seoul National University College of Medicine   (South Korea)

^b Isu Abxis Co Ltd   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

ATP based chemotherapy response assay; Individualized tumor response testing (ITRT); Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BELOTECAN; CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; OXALIPLATIN; PACLITAXEL; TOPOTECAN;

ACCURACY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL ISOLATION; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; TUMOR CELL; TUMOR CELL CULTURE;

ADENOSINE TRIPHOSPHATE; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; SINGLE-BLIND METHOD; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 42649143263     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900701813250     Document Type: Article

References (30)

1. Jemal, A.; Siegel, R.; Ward, E.; Murray, T.; Xu , J.; et al. Cancer statistics, 2006. CA Cancer J Clin 2006, 56(2), 106-130.
2. McGuire, W.P.; Hoskins, W.J.; Brady, M.F.; Kucera, P.R.; Partridge, E.E.; et al. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol 1996, 23(5 Suppl 12), 40-47.
3. Ozols, R.F.; Bundy, B.N.; Greer, B.E.; Fowler, J.M.; Clarke-Pearson, D.; et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003, 21(17), 3194-3200.
4. Cree, I.A.; Kurbacher, C.M. Individualizing chemotherapy for solid tumors-is there any alternative? Anticancer Drugs 1997, 8 (6), 541-548.
5. Weisenthal, L.M.; Marsden, J.A.; Dill, P.L.; Macaluso, C.K. A novel dye exclusion method for testing in vitro chemosensitivity of human tumors. Cancer Res 1983, 43 (2), 749-757.
6. Kern, D.H.; Drogemuller, C.R.; Kennedy, M.C.; Hildebrand-Zanki, S.U.; Tanigawa, N.; Sondak, V.K. Development of a miniaturized, improved nucleic acid precursor incorporation assay for chemosensitivity testing of human solid tumors. Cancer Res 1985, 45(11 Pt 1), 5436-5441.
7. Andreotti, P.E.; Cree, I.A.; Kurbacher, C.M.; Hartmann, D.M.; Linder, D.; et al. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 1995, 55 (22), 5276-5282.
8. Sevin, B.U.; Peng, Z.L.; Perras, J.P.; Ganjei, P.; Penalver, M.; Averette, H.E. Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing. Gynecol Oncol 1988, 31 (1), 191-204.
9. Cree, I.A.; Kurbacher, C.M.; Untch, M.; Sutherland, L.A.; Hunter, E.M.; et al. Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. Anticancer Drugs 1996, 7 (6), 630-635.
10. O'Meara, A.T.; Sevin, B.U. Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer. Gynecol Oncol 2001, 83 (2), 334-342.
11. Kawamura, H.; Ikeda, K.; Takiyama, I.; Terashima, M. The usefulness of the ATP assay with serum-free culture for chemosensitivity testing of gastrointestinal cancer. Eur J Cancer 1997, 33 (6), 960-966.
12. Konecny, G.; Crohns, C.; Pegram, M.; Felber, M.; Lude, S.; et al. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer. Gynecol Oncol 2000, 77 (2), 258-263.
13. Sharma, S.; Neale, M.H.; Di, Nicolantonio, F.; Knight, L.A.; Whitehouse, P.A.; et al. Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma. BMC Cancer 2003, 3, 19.
14. Kang, S.M.; Park, M.S.; Chang, J.; Kim, S.K.; Kim, H.; Shin, D.H. A Feasibility Study of Adenosine Triphosphate-based Chemotherapy Response Assay (ATP-CRA) as a Chemosensitivity Test for Lung Cancer. Cancer Res Treat 2005, 37 (4), 223-227.
15. Moon, Y.W.; Choi, S.H.; Kim, Y.T.; Sohn, J.H.; Chang, J.; et al. Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer. Cancer 2007, 109 (9), 1829-1835.
16. Iinuma, H.; Okinaga, K.; Adachi, M.; Suda, K.; Sekine, T.; et al. Detection of tumor cells in blood using CD45 magnetic cell separation followed by nested mutant allele-specific amplification of p53 and K-ras genes in patients with colorectal cancer. Int J Cancer 2000, 89 (4), 337-344.
17. Weisenthal, L.M.; Dill, P.L.; Finklestein, J.Z.; Duarte, T.E.; Baker, J.A.; Moran, E.M. Laboratory detection of primary and acquired drug resistance in human lymphatic neoplasms. Cancer Treat Rep 1986, 70 (11), 1283-1295.
18. Bird, M.C.; Bosanquet, A.G.; Gilby, E.D. In vitro determination of tumour chemosensitivity in haematological malignancies. Hematol Oncol 1985, 3 (1), 1-10.
19. Von, Hoff, D.D.; Casper, J.; Bradley, E.; Sandbach, J.; Jones, D.; Makuch, R. Association between human tumor colony-forming assay results and response of an individual patient's tumor to chemotherapy. Am J Med 1981, 70 (5), 1027-1041.
20. Therasse, P.; Arbuck, S.G.; Eisenhauer, E.A.;Wanders, J.; Kaplan, R.S.; et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92 (3), 205-216.
21. Rustin, G.J.; Quinn, M.; Thigpen, T.; du, Bois, A.; Pujade-Lauraine, E.; et al. Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 2004, 96 (6), 487-488.
22. Jeong, J.; Lee, S.; Yoon, S.; Jung, W.; Lee, H.; Lee, I. Clinical availability of chemotherapy response assay using adenosine triphosphate in breast cancer patients. Proceedings of the American Society of Clinical Oncology 2006, Abstract 15592.
23. Kim, B.S.; Ahn, Y.M.; Kim, J.; Yoon, E.J.; Choi, S.H. Clinical utility of adenosine triphosphate-based chemosensitivity response assay (ATP-CRA) in non-small cell lung cancer: Preliminary study. Proceedings of the American Society of Clinical Oncology 2004, Abstract 7259.
24. Kim, H.A.; Yom, C.K.; Moon, B.I.; Choe, K.J.; Sung, S.H.; et al. The use of an in vitro adenosine triphosphate-based chemotherapy response assay to predict chemotherapeutic response in breast cancer. Breast 2007, July 27.
25. Ng, T.Y.; Ngan, H.Y.; Cheng, D.K.; Wong, L.C. Clinical applicability of the ATP cell viability assay as a predictor of chemoresponse in platinum-resistant epithelial ovarian cancer using nonsurgical tumor cell samples. Gynecol Oncol 2000, 76 (3), 405-408.
26. Ozols, R.F. Chemotherapy of ovarian cancer. Cancer Treat Res 1998, 95, 219-234.
27. Schrag, D.; Garewal, H.S.; Burstein, H.J.; Samson, D.J.; Von, Hoff, D.D.; Somerfield, M.R. American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol 2004, 22 (17), 3631-3638.
28. Cortazar, P.; Johnson, B.E. Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer. J Clin Oncol 1999, 17 (5), 1625-1631.
29. Orr, J.W., Jr.; Orr, P.; Kern, D.H. Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance. Cancer J Sci Am 1999, 5 (3), 174-178.
30. Smith, N.F.; Marsh, S.; Scott-Horton, T.J.; Hamada, A.; Mielke, S.; et al. Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther 2007, 81 (1), 76-82.